Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019693 (HIV)
 170,526 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

DuPont Merck, manufacturer of the experimental drug efavirenz (Sustiva, DMP-266), has issued a warning to researchers and physicians concerning birth defects found in 3 of 13 monkey fetuses whose mothers took the drug throughout gestation. Researchers believe that the abnormalities manifested in the early stages of pregnancy. Human trials require participants to use birth control, but now strongly emphasize not becoming pregnant while taking the drug. Efavirenz has not demonstrated harm in late pregnancy and may be used in future trials to block maternal/fetal transmission of HIV.
 ...
PMID:Notice on efavirenz and pregnancy. 1136 85

Four new drugs have been developed to overcome the limitations of the currently available anti-HIV drugs, including inconvenient schedules, side effects, and drug interactions. It is hoped that abacavir, efavirenz, adefovir dipivoxil, and amprenavir will be widely available in the near future. Abacavir, a nucleoside reverse transcriptase inhibitor with a twice-daily schedule, offers good bioavailability and generally mild side effects. Efavirenz, a non-nucleoside reverse transcriptase inhibitor with a once daily schedule, may produce side effects such as rash and dizziness. Adefovir dipivoxil, a nucleotide analog with once daily dosing, can cause carnitine depletion and carnitine supplementation is recommended. Amprenavir, a protease inhibitor with twice-daily dosing, has rather mild side effects. Information on efficacy, availability, and resistance for each of these drugs is given.
 ...
PMID:Antiretroviral agents: the next generation. 1136 27

The Food and Drug Administration (FDA) is considering expediting the approval process of efavirenz, a NNRTI drug. If efavirenz is approved, it could be available by late summer. Efavirenz has produced undetectable viral levels, with or without the use of a protease inhibitor. Assessment of its long-term viability in suppressing HIV, without using protease inhibitors, will be presented at the AIDS conference in Geneva by its manufacturer, DuPont Merck. Further information about treatment programs is provided.
 ...
PMID:Efavirenz (Sustiva) on fast-track for FDA accelerated approval. Food and Drug Administration. 1136 71

Efavirenz, an NNRTI, has been approved by the U.S. Food and Drug Administration. Efavirenz is taken once daily and is used in combination with other drugs. Efavirenz is also able to strike HIV in the brain, which may prevent some possible neurological conditions. Some side effects of efavirenz may affect the central nervous system. However, these side effects may be reduced by taking the dose at bedtime. An expanded access program is available in Canada.
 ...
PMID:Efavirenz approved in the U.S. 1136 76

Efavirenz (Sustiva) is a potent anti-HIV medication that is comparable to Indinavir in lowering viral load and elevating CD4+ counts. One negative side effect of efavirenz is that it may cause false positive results on tests for marijuana use. Confirmatory tests can establish the presence of efavirenz rather than marijuana. Tests used in Canada to detect the presence of marijuana are listed.
 ...
PMID:Efavirenz use may cause false positive result for marijuana. 1136 77

Efavirenz and abacavir, two recently approved drugs, have simplified HIV treatment. They are taken less often than some other drugs, and fewer pills are required. Results are reported from studies which have evaluated different dosing schedules and the effectiveness of new drug combinations. The studies have involved AZT, Combivir, d4T, amprenavir, Indinavir, Ritonavir, and Delavirdine. Researchers hope that the results of these studies may provide alternatives to three times a day dosing schedules.
 ...
PMID:Antiviral therapy: how simple can you get? 1136 6

Efavirenz (Sustiva) is the first once-daily dosing anti-HIV drug approved by the Food and Drug Administration. The non-nucleoside reverse transcriptase inhibitor (NNRTI) is highly potent and more convenient than other therapies, and is used to treat HIV-1 in both adults and pediatric patients. It is effective in combination therapy, and patients on efavirenz had fewer side effects than patients on other triple combinations therapies. It remains to be seen if efavirenz will be used in first-line therapy. Some reports show that patients who are taking other drugs that affect the central nervous system suffer additional central nervous system side effects from efavirenz. There are reports of cross-resistance with other drugs in the same class, and limited data that is available on fetal toxicity suggests that women of childbearing age need to be counseled carefully before taking this drug.
 ...
PMID:First once-daily drug simplifies dosing, offers new options in HIV-1 treatment. 1136 67

The Food and Drug Administration (FDA) approved DuPont Pharma's new non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (Sustiva, DMP-266). Efavirenz has shown promise in trials with over 2000 participants for up to 24 weeks, and early data suggests it may be as effective as protease inhibitors when used in a combination regimen. It is the first anti-HIV drug approved for once-daily dosing. Efavirenz is well tolerated, and the main side effects reported are dizziness, insomnia, abnormal dreams, and skin rash. Efavirenz has been approved for adults and children, but should not be used by pregnant women. Contact information is provided.
 ...
PMID:FDA approves efavirenz. Food and Drug Administration. 1136 87

The newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (Sustiva), was added to the Department of Health and Human Services' (DHHS) "Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents" as a preferred component of combination anti-HIV therapy, in 1998. Efavirenz is the first non-protease inhibitor drug to be included as a preferred agent. The other NNRTIs, nevirapine and delavirdine, are included as "alternative" recommendations. More information was added to the guidelines, including adverse effects of anti-HIV drugs and drug resistance testing. A web address for the full guidelines is provided.
 ...
PMID:Government updates HIV treatment guidelines. 1136 34

Several sessions at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) presented results of trials of anti-HIV drugs. ABT-378/r, a combination of the protease inhibitor ABT-378 with ritonavir, shows great promise. T-20 (pentafuside) shows significant benefits in treating advanced HIV disease. Tenofovir DF (PMPA) appears to have benefits in treating people who are taking four or fewer other drugs. Efavirenz (Sustiva) in combination with AZT and 3TC continues to show effectiveness at 72 weeks. Once-daily dosing regimens are also under development, which should make adherence to treatment programs easier for patients.
 ...
PMID:Anti-HIV therapy trials: new studies and follow-up of existing trials. 1136 57


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>